Welcome to our dedicated page for CELLECTAR BIOSC news (Ticker: CLRBZ), a resource for investors and traders seeking the latest updates and insights on CELLECTAR BIOSC stock.
Cellectar Biosciences (NASDAQ: CLRBZ) is a clinical-stage biopharmaceutical company advancing targeted cancer therapies through its proprietary Phospholipid Drug Conjugate™ (PDC™) platform. This page provides investors, researchers, and healthcare professionals with timely updates on the company’s clinical developments, regulatory milestones, and strategic initiatives.
As a centralized resource for CLRBZ-related news, this page offers critical insights into ongoing clinical trials for assets like iopofosine I-131 and next-generation radiopharmaceutical programs. Users will find verified updates on FDA designations, partnership announcements with industry leaders such as SpectronRx, and progress reports on manufacturing scalability.
Key content categories include updates on:
- Clinical trial results for Waldenstrom’s macroglobulinemia and multiple myeloma
- Regulatory developments, including Orphan Drug and Fast Track designations
- Strategic collaborations impacting drug development and supply chain operations
- Financial disclosures and corporate communications
Bookmark this page to stay informed about Cellectar’s innovations in precision oncology and its mission to address unmet needs in cancer treatment.
Cellectar Biosciences (NASDAQ: CLRB) has announced plans to explore strategic alternatives to maximize stockholder value. The company, which focuses on cancer drug development, is considering various options including mergers, acquisitions, partnerships, joint ventures, and licensing arrangements.
The company has engaged Oppenheimer & Co as exclusive financial advisor for the strategic evaluation process. CEO James Caruso highlighted their key asset iopofosine I 131, along with alpha- and Auger-emitting radioconjugates (CLR 225 and CLR 125) for solid tumor treatments.
While no specific timetable has been set for the evaluation process, Cellectar emphasizes that no agreements have been reached, and there are no guarantees that the process will result in any transaction. The company will only disclose further information when deemed necessary.
Cellectar Biosciences (NASDAQ: CLRB) reported financial results for 2024 and provided corporate updates. The company achieved FDA alignment for potential accelerated approval of iopofosine I 131 for Waldenström macroglobulinemia (WM) treatment. The Phase 2 CLOVER-WaM study showed an 83.6% Overall Response Rate and 58.2% Major Response Rate.
Financial highlights include cash and equivalents of $23.3 million as of December 31, 2024, compared to $9.6 million in 2023. The company raised $44.1 million through warrant exercises in January 2024 and $19.4 million in July 2024. R&D expenses decreased to $26.1 million from $27.3 million, while G&A expenses increased to $25.6 million from $11.7 million. Net loss was $44.6 million ($1.22 per basic share).
The company plans Phase 1 solid tumor studies with two radioconjugate compounds: CLR 121125 for triple-negative breast cancer and CLR 121225 for pancreatic cancer, with an IND submission planned for first half 2025.
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company specializing in cancer treatment drug development, has announced its participation in the 37th Annual Roth Conference. The company's management team will deliver a corporate presentation on Monday, March 17, 2025, at 8:30 AM Eastern Time.
The presentation will provide an overview of the company and its operations. Interested parties can access the presentation through a webcast link, and a replay will be made available in the Events section of Cellectar's Investor Relations website.
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company specializing in cancer treatment drug development, has scheduled its full year 2024 financial results announcement and corporate update for March 13, 2025, at 8:30 a.m. Eastern Time. The company will make a replay of the conference call available through their Investor Relations website's Events section.
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company specializing in cancer treatment drug development, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management team will deliver a corporate presentation on Wednesday, February 12, 2025, at 12:00 PM Eastern Time.
The conference will be held virtually, and interested parties can access the presentation through a provided webcast link. Following the live presentation, a replay will be made available in the Events section of Cellectar's investor relations website.
Cellectar Biosciences (NASDAQ: CLRB) announced its 2025 strategic initiatives, highlighting significant progress with its cancer treatment drug Iopofosine I 131. The company reported impressive Phase 2 CLOVER-WaM study results, achieving an 83.6% overall response rate and exceeding primary endpoints in treating Waldenstrom's Macroglobulinemia.
The company is finalizing its confirmatory study for FDA accelerated approval and EMA authorization, expecting to enroll 40-60 patients per arm with completion projected within 18 months. Cellectar's cash runway extends into Q4 2025, and they're exploring various approaches to commercialize Iopofosine.
Additionally, Cellectar is advancing two other radiotherapeutic assets: CLR 121225, an alpha-emitting radioconjugate showing promising results in solid tumor models, with IND filing planned for Q1 2025, and CLR 121125, an Auger-emitting PRC with IND clearance for triple-negative breast cancer trials.
Cellectar Biosciences (NASDAQ: CLRB) announces strategic changes, including pursuing options for iopofosine I 131 development following FDA communications regarding confirmatory study requirements. The company will shift focus to advancing its alpha- and Auger-emitting radioconjugates into Phase 1 solid tumor studies.
The FDA indicated that accelerated approval would require major response rate data from CLOVER-WaM study and enrollment in a randomized controlled confirmatory study for progression-free survival data. The company plans to file Investigational New Drug applications for CLR-121225 and CLR-121125 in first half of 2025.
As part of restructuring, Cellectar will reduce headcount by approximately 60% by end of Q4 2024, extending cash runway into Q3 2025.
Cellectar Biosciences reported Q3 2024 financial results and corporate updates. The company reported positive results from Phase 2 CLOVER-WaM pivotal study for iopofosine I 131 in Waldenstrom's macroglobulinemia treatment. The company raised $19.4 million through warrant exercises with potential for additional $73.3 million. Cash position stood at $34.3 million as of September 30, 2024. R&D expenses decreased to $5.5 million from $7.0 million year-over-year, while G&A expenses increased to $7.8 million from $2.4 million. The company plans to file NDA submission in the coming months.
Cellectar Biosciences (NASDAQ: CLRB) has signed a strategic 10-year supply agreement with NorthStar Medical Radioisotopes for non-carrier-added Actinium-225 (Ac-225), a rare radioisotope essential for cancer treatment. The agreement supports Cellectar's CLR 121225 development program, which combines their Phospholipid Ether delivery platform with Ac-225 for solid tumor treatment.
The company plans to begin human clinical trials in 2025, following promising preclinical results in pancreatic, triple negative breast, and other solid tumors. This partnership addresses the critical challenge of Ac-225 scarcity in clinical development and commercialization, securing a reliable supply source for Cellectar's radiotherapeutic development strategy.
Cellectar Biosciences (NASDAQ: CLRB) and SpectronRx have signed a commercial supply agreement for manufacturing iopofosine I 131, a first-in-class cancer therapy. SpectronRx will produce the treatment at facilities in Indiana and Belgium, supporting Cellectar's planned 2025 commercialization. The drug has shown promising results in the CLOVER-WaM pivotal study for Waldenstrom's macroglobulinemia and is being evaluated in Phase 2 studies for multiple myeloma and CNS lymphoma, as well as a Phase 1b study for pediatric high-grade gliomas. The partnership strengthens Cellectar's global manufacturing network and distribution capabilities.
